GlassScriptPhysician profile
Mohammad H Yousaf
NPI 1801844303
$9,430.58
in general payments reported to CMS, 2019-2025
43 companies · $2,107 in 2025
The $2,107 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,559 · 2022: $2,181 · 2023: $1,128 · 2024: $1,457 · 2025: $2,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,690.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,683.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,030.37 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $898.18 | 2021-2025 | |
| Pfizer INC. | $707.12 | 2021-2025 | |
| Amgen INC. | $668.33 | 2021-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $575.29 | 2021-2023 | Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $554.51 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $436.73 | 2021-2025 | |
| Amarin Pharma, INC. | $275.52 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $224.35 | 2021 | |
| Merck Sharp & Dohme LLC | $215.88 | 2021-2022 | |
| Astellas Pharma US INC | $183.83 | 2021-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $171.17 | 2021-2022 | |
| Glaxosmithkline, LLC. | $161.89 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $152.97 | 2021-2025 | Dexcom G6 Transmitter |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Yousaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.